Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ANI PHARMACEUTICALS INC entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $75 million (effective 2023-05-11).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Guggenheim Securities, LLC
- Value
- approximately $75 million
- Effective
- 2023-05-11
Exact text from the filing
On May 11, 2023, ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”) priced its previously announced underwritten public offering pursuant to which the Company has agreed to issue and sell an aggregate of 1,898,735 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $39.50 per share, for aggregate gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the offering (the “Offering”). Pursuant to the terms of the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between the Company and Guggenheim Securities, LLC (the “Underwriter”), the Company granted to the Underwriter a 30-day option to purchase up to an additional 284,810 shares of Common Stock.
View on SEC.gov